Nektar Therapeutics Files 8-K on Shareholder Vote
Ticker: NKTR · Form: 8-K · Filed: Jun 6, 2024 · CIK: 906709
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: NKTR
TL;DR
Nektar Therapeutics had a shareholder vote on June 5th, details to follow.
AI Summary
Nektar Therapeutics filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 5, 2024. The filing does not contain specific details about the vote's outcome or the proposals presented.
Why It Matters
This filing indicates a shareholder vote occurred, which could signal significant corporate decisions or changes being considered by Nektar Therapeutics.
Risk Assessment
Risk Level: low — The filing is a routine procedural report and does not contain information that immediately suggests significant financial or operational risk.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- June 6, 2024 (date) — Filing Date
- June 5, 2024 (date) — Earliest Event Reported Date
FAQ
What specific matters were submitted to a vote of Nektar Therapeutics' security holders on June 5, 2024?
The filing does not specify the exact proposals or matters that were put to a vote.
What was the outcome of the shareholder vote on June 5, 2024?
The filing does not disclose the results or outcome of the shareholder vote.
When was the 8-K filing submitted to the SEC?
The 8-K filing was submitted on June 6, 2024.
What is Nektar Therapeutics' principal executive office address?
Nektar Therapeutics' principal executive offices are located at 455 Mission Bay Boulevard South, San Francisco, California 94158.
What is Nektar Therapeutics' IRS Employer Identification Number?
Nektar Therapeutics' IRS Employer Identification Number is 94-3134940.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2024-06-06 16:05:42
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0207441-8k_nektar.htm (8-K) — 34KB
- 0001213900-24-050365.txt ( ) — 202KB
- nktr-20240605.xsd (EX-101.SCH) — 3KB
- nktr-20240605_lab.xml (EX-101.LAB) — 33KB
- nktr-20240605_pre.xml (EX-101.PRE) — 22KB
- ea0207441-8k_nektar_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders At the Annual Meeting of the Stockholders of Nektar Therapeutics, a Delaware corporation (the "Company"), held on June 5, 2024 (the "Annual Meeting"), the following actions were taken. The proposals below are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 26, 2024. Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2027 Annual Meeting of Stockholders. Nominee For Against Abstain Broker Non-Votes Jeff Ajer 89,572,592 5,310,752 5,112,487 46,683,689 Robert B. Chess 87,385,092 7,518,984 5,091,755 46,683,689 Roy A. Whitfield 85,885,290 8,993,582 5,116,959 46,683,689 In addition to the directors elected above, Diana Brainard, R. Scott Greer and Howard W. Robin continue to serve as directors after the Annual Meeting. Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 8,000,000 shares was approved with the following votes. For Against Abstain Broker Non-Votes 86,500,506 7,507,037 5,988,288 46,683,689 Proposal 3 The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved with the following votes. For Against Abstain Broker Non-Votes 139,098,119 1,556,508 6,024,893 0 Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes. For Against Abstain Broker Non-Votes 87,037,178 6,730,748 6,227,905 46,683,689
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: June 6, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2